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PART I: INTRODUCTION
Although Substance Use Disorder (“SUD”) is a medically recognized disease1, popular
stigma still views it as a choice. This causes patients suffering from SUD to deal with negative
implications in their daily lives. Federal legislation, such as 42 C.F.R. § 22 (“Part 2”) provide
essential privacy protections to these patients—ensuring treatment records are not disclosed
without the patient’s consent. These protections are essential because anti-discriminatory laws,
such as the Americans With Disabilities Act3 (“ADA”), fail to protect patients suffering from
SUD. Recently, lobbying efforts to amend Part 2 have gained traction. Supporters of amending
Part 2 claim that it hinders medical providers from providing collaborative care.
This comment will analyze Part 2, discuss the protections it provides, and lastly, assert that
these protections must remain in place. It will offer solutions to mitigate the concerns of medical
providers who claim Part 2 hinders the delivery of collaborated care.
Part II of this note will give a brief history of SUD, its recognition as a medical disease, the
stigma surrounding it, and the legal and practical consequences of such stigma. Part III will
detail the protections provided by Part 2. Part IV will analyze the failure of anti-discriminatory
laws to protect patients suffering from SUD. Part V will summarize the arguments posed by
those in favor of amending Part 2. Part VI will discuss Prescription Drug Monitoring Programs
(“PDMPs”) and their role in monitoring prescription drug use. Part VII, incorporating the use of

1

Mayo Clinic, Diseases and Conditions; available at https://www.mayoclinic.org/diseases-conditions/drugaddiction/symptoms-causes/syc-20365112.
2
42 U.S.C. 290dd-2.
3
42 U.S.C. § 12101-12117.
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PDMPs, proposes a solution to protect the privacy of SUD patients while also addressing the
concerns of medical providers who support amending Part 2. Namely, this comment proposes
that State PDMP programs should expand access to SUD providers and mandate frequent and
consistent checks of the PDMP. This comment aims to highlight the negative implications
patients suffering from SUD face, address the arguments posed by proponents of removing Part
2’s protections, and provide a solution to mitigate these concerns while still maintaining the
essential protections of Part 2.
PART II: ILLNESS AND STIGMA
SUD is a disease effecting millions of Americans4. A majority of medical professionals
agree that SUD is an illness, rather than a choice made by the patient5. Despite such medical
findings, negative stigma towards SUD and its victims is still very prevalent6. The ramifications
of this stigma result in practical, legal, and medical consequences for patients.
SUD GENERALLY
SUD effects a large number of Americans; in 2017, an estimated 19.7 million Americans
suffered from substance use disorder.7 SUD is a disease that affects a person’s brain and
behavior, leading to an inability to control the use of a legal or illegal drug, substance, or
medication.8 The term “drugs” encompasses prescription drugs, such as prescription opioid
painkillers, alcohol, marijuana, and nicotine.9 SUD is recognized as a primary, progressive,

4

Substance Abuse and Mental Health Services Administration (SAMHSA), 2017 NSDUH Annual National Report,
(2018); available at https://www.samhsa.gov/data/report/2017-nsduh-annual-national-report.
5
Mental Health America supra note 4; see also American Psychiatric Association, Diagnostic and Statistical
Manual of Mental Disorders (DSM-5), available at https://www.psychiatry.org/psychiatrists/practice/dsm.
6
SAMHSA supra note 4.
7
Id.
8
Mayo Clinic supra note 1.
9
Id. (explaining that non-illegal substances such as alcohol and nicotine are considered “drugs”).
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chronic, relapsing and treatable disease10, caused by both environmental factors and genetics.11
Medical professionals have consistently found that SUD “remolds” the brain’s chemistry,
causing patients to ignore health concerns, work obligations, and family.12 Medical research has
also suggested that certain individuals are predisposed to SUD.13 Contrary to popular belief, the
medical community is in agreement that SUD does not stem from a decision made by the patient,
but is rather a medical condition14. SUD is also often accompanied with mental health
disorder.15 Of the roughly 20 million16 Americans suffering from SUD, 41.2 percent also
suffered from a mental health disorder.17 It is evident that SUD is an epidemic in America that
requires extreme care from by the healthcare system.18
STIGMA SURROUNDING SUD
Stigma is defined as “a set of negative beliefs that a group or society holds about a topic
or group of people.”19 Although, as mentioned above, SUD is recognized in the medical
community as a chronic medical disease, studies show that many people view it as a moral
failing and perceive patients negatively.20 Public stigma regarding SUD patients is very

10

Mental Health America, Position Statement 33: Substance Use Disorders; available at
https://www.mhanational.org/issues/position-statement-33-substance-use-disorders (explaining that SUD is a
disease).
11
Mayo Clinic supra note 1 (finding that SUD is caused by both environmental factors and genetics).
12
Mental Health America supra note 6; see also American Psychiatric Association, Diagnostic and Statistical
Manual of Mental Disorders (DSM-5), available at https://www.psychiatry.org/psychiatrists/practice/dsm.
13
Moffit, Arseneault, Belsky, et al: A gradient of childhood self-control predicts health, wealth, and public safety,
Proc Nat’l Acad. Sci. USA, 2693, 2698, 2011; available at https://www.pnas.org/content/pnas/108/7/2693.full.pdf.
14
Id.
15
Supra note 6.
16
Supra note 4.
17
Supra note 7.
18
Mental Health America, Position Statement 33: Substance Use Disorders; available at
https://www.mhanational.org/issues/position-statement-33-substance-use-disorders (explaining the harsh reality of
SUD in America and the need to address the issue from a healthcare collaborative approach).
19
Lauren Villa, Shaming The Sick: Addiction and Stigma, DrugAbuse.com,
https://drugabuse.com/addiction/stigma/.
20
Colleen L. Barry, Emma Elizabeth McGinty, Bernice Pescosolido, Howard H. Goldman, Stigma, Discrimination,
Treatment Effectiveness and Policy Support: Comparing Public Views about Drug Addiction with Mental Illness,
Psychiatr. Serv. 2014 Oct; 65(10): 1269–1272. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285770/.
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prevailing and has real-word consequences.21 Such stigma and discrimination causes legal and
practical ramifications. Many times, the patient being treated for SUD treatment, not the actual
use of an illegal substance, was the reason patients were discriminated against.22 For example,
parents have been denied visiting rights to their children even when they were in recovery and
not actively engaged in drug use.23 Patients were evicted from shelters because they were being
treated for opioid addiction.24
Stigma surounding SUD patients also effects public housing eligibility.25 A study by the
U.S. Department of Housing and Urban Development found that almost all Public Housing
Authorities (“PHAs”) enforce bans against individuals with history of alcohol or drug use far
more stringent than required by federal law.26 PHAs also used a great deal of discretion in
determining housing rights of such individuals.27 Because of the negative stigma towards SUD
patients, these discretionary decisions by PHAs have resulted in negative consequences for
patients.28
Besides having practical and real world ramifications, fear of judgement and implications
from others both deters patients from entering treatment and results in poor treatment.29 A Dutch
university conducted a study evaluating health professionals’ attitudes towards patients with
SUD and the ramifications of these attitudes on the healthcare delivery system in Western

See, K. Lopez, D. Reid “Discrimination Against Patients With Substance Use Disorders Remains Prevalent And
Harmful: The Case For 42 CFR Part 2” Health Affairs, April 13, 2017, available at
https://www.healthaffairs.org/do/10.1377/hblog20170413.059618/full/ (citing examples of stigma consequences
effecting patients).
22
Id.
23
Id.
24
Id.
25
Marah A. Curtis et. al, Alcohol, Drug, and Criminal History Restrictions in Public Housing;
https://www.huduser.gov/portal/periodicals/cityscpe/vol15num3/ch2.pdf
26
Id.
27
Id.
28
Id.
29
Villa supra note 15.
21
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countries.30 This study found that health professionals had a negative attitude towards patients
suffering from SUD and entered the treatment of those individuals with stigma and bias.31 Those
professionals “perceived violence, manipulation, and poor motivation as impeding factors in the
healthcare delivery for these patients.”32 The study also found that negative attitudes from
professionals had a negative impact on patients’ comfort in the healthcare process.33 Similarly, a
British study interviewed a mix of patients suffering from SUD and treating registered nurses.34
The study found that the two most prevalent issues in the nurse-SUD patient relationship were
“lack of knowledge to care” and “distrust and detachment”.35 The study also found that nurses
pre-judged their SUD patients, and as a result, patients were disconnected with their care
providers increasing conflict, disruption, and violence.36
It is evident that SUD is a prevalent disease in America and stigma surrounding it
negatively impacts patients. The current stigma causes SUD patients to be discriminated against
both legally and procedurally in matters such as custody of children and housing rights. Stigma
further discourages SUD from seeking treatment and disadvantages them in the healthcare
delivery process. The negative implications of SUD stigma are real and pervasive.
Part III: PROTECTING SUD PATIENTS THROUGH 42 C.F.R.§ 2

30

van Boekel, Brouwers, van Weeghel, Garretson, Stigma among health professionals towards patients with
substance use disorders and its consequences for healthcare delivery: systematic review, Drug Alcohol
Depend. 2013 Jul 1;131(1-2):23-35; https://www.ncbi.nlm.nih.gov/pubmed/23490450.
31
Id.
32
Id.
33
Id. (“Negative attitudes of health professionals diminished patients' feelings of empowerment and subsequent
treatment outcome.”)
34
Monks, R., Topping, A., & Newell, R. The dissonant care management of illicit drug users in medical wards, the
views of nurses and patients: A grounded theory study. Journal of advanced nursing, 69(4), 935-946 (2013),
(https://www.ncbi.nlm.nih.gov/pubmed/22776007) .
35
Id.
36
Id.
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42 C.F.R. § 2, better known as Part 2 was enacted in 1987 and is codified in 42 U.S.C.
290dd-2.37 Part 2 was enacted by Congress to respond to the fear that stigma would dissuade
individuals from seeking SUD treatment.38 Specifically, the legislative history of Part 2 cites a
fear of SUD records being negatively used against patients.39 The regulations are also aimed at
ensuring that a patient who is seeking treatment for SUD is not made more vulnerable due to the
risk of treatment records being disseminated.40 The Department of Health and Human Services,
in the Federal Register, has acknowledged that disclosure of SUD records may lead to a variety
of negative consequences for the patient.41
Part 2 creates an extra layer of protection for patients, providing for a limited set of
circumstances where a patient’s treatment record may be disclosed without such patient's
knowledge.42 In sum, Part 2 applies to any “federally assisted… individual or entity (other than
a general medical facility) who holds itself out as providing, and provides, substance use disorder
diagnosis, treatment, or referral for treatment.”4344 It requires that the records, identity,
diagnosis, or treatment records of any patient which are kept as part of a substance abuse

37

42 U.S.C. 290dd-2.
Susan Awad, Confused by Confidentiality? A Primer on 42 CFR Part 2, American Society of Addiction
Medicine, https://www.asam.org/resources/publications/magazine/read/article/2013/08/15/confused-byconfidentiality-a-primer-on-42-cfr-part-2
39
Confidentiality of Substance Use Disorder Patient Records, 82 Fed. R. 6052, 6053 (Jan 18, 2017). Federal
Register: The Daily Journal of the United States. Web. 18 Jan 2017,
https://www.federalregister.gov/documents/2017/01/18/2017-00719/confidentiality-of-substance-use-disorderpatient-records#h-9.
40
Id.
41
Id. (disclosure may lead to “[l]oss of employment, loss of housing, loss of child custody, discrimination by
medical professionals and insures, arrest, prosecution, and incarceration).
42
Id.
43
42 C.F.R. §2.11
44
“Most drug and alcohol treatment programs are federally assisted. For-profit programs and private practitioners
that do not receive federal assistance of any kind would not be subject to the requirements of [Part 2] unless the
State licensing or certification agency requires them to comply. However, any clinician who uses a controlled
substance for detoxification or maintenance treatment of [SUD] requires a federal DEA registration and becomes
subject to [Part 2] through th[at] DEA license.” Awad supra note 34.
38
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treatment or rehabilitation program be kept confidential, except for a few circumstances.45
Besides the exceptions46, the only way qualified SUD treatment records may be disclosed to any
party is through prior written consent of the patient.4748
PART IV: FAILURE OF ANTI-DISCRIMINATORY LEGISLATION TO PROTECT
SUD PATIENTS
Current federal legislation, such as the Americans With Disabilities Act49 (“ADA”), fails
to protect patients suffering from SUD from the consequences of negative stigma surrounding
their disease50. The ADA does not protect individuals engaged in current illegal drug use. 51 This
prevents patients suffering from SUD from being protected by anti-discriminatory laws available
to other Americans, causing these patients to suffer severe consequences.
THE ADA GENERALLY
The ADA, enacted in 1990, is a civil rights law which prohibits the discrimination against
individuals suffering from disabilities.52 The ADA mandates that qualified individuals be
protected from discrimination in employment, education, transportation, and all public and
private places which are accessible by the general public.53 The goal of the ADA is to ensure
that American’s with disabilities are ensured the same rights and access as those without

45

42 U.S.C. 290dd-2(a).
42 U.S.C. 290dd-2(b)(2)(A)-(C) (listing the following exceptions; (i) during a medical emergency, (ii) to qualified
personnel for scientific research provided that identities remain confidential, and (iii) and if authorized by court
order).
47
42 U.S.C. 290-dd-2(b)(1).
48
It is important to note the contrast of Part 2 to the Health Insurance Portability and Accountability Act
(“HIPAA”), which allows a health care provider to alert family or law enforcement of illegal drug use. See
generally 45 C.F.R. § 164.512(j).
49
42 U.S.C. § 12101-12117.
50
See Nielsen v. Moroni Feed Co., 162 F.3d 604, 611 n.12 (the ACA did not protect an employee who was
discharged for addiction stemming from prescription drugs).
51
42 U.S.C. § 12114 (under the ADA individuals “currently engaging in the illegal use of drugs” are not covered).
52
ADA National Network, What is The Americans With Disabilities Act (ADA)?, https://adata.org/learn-about-ada.
53
Id.
46
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disabilities.54 The ADA provides protections to individuals on the basis of disability similar to
the constitutional protections afforded to individuals on the basis of race, sex, age, and religion.55
The ADA, however, treats individuals suffering from SUD using illicit substances, different than
individuals suffering from other medical diseases.56 Under the ADA, an individual who is
currently engaging in the illegal use of drugs is not classified as an “individual with a
disability”.57
DEFINING “CURRENT ILLEGAL DRUG USE” UNDER THE ADA
“Illegal use”, as defined by the ADA, encompasses more than just the use of “street
drugs”. It also encompasses the use of prescription drugs.58
Because only individuals who are “currently” using illegal drugs are excluded from ADA
protection59, defining the use of “current” is essential. The Equal Opportunity Commission
("EEOC") has defined “current” to mean that an individual had used a drug “recently enough” to
justify an employer believing that the employee’s use is an ongoing problem.60 The EEOC has
further explained that “[current drug use] is not limited to the day of use, or recent weeks or
days, in terms of an employment action.”.61 The EEOC further notes that an employee who tests
positive, but is in a treatment program, or seeks treatment, is not entitled to protection.62

54

Id.
Id.
56
Sharing the Dream: Is the ADA Accommodating All? Chapter 4: Substance Abuse under the ADA, United States
Commission on Civil Rights, https://www.usccr.gov/pubs/ada/ch4.htm.
57
42 U.S.C. § 12114(a).
58
See Nielsen v. Moroni Feed Co., 162 F.3d 604, 611 n.12 (10th Cir. 1998) (“[there] is no doubt that, under the
ADA, illegal drug use includes the illegal misuse of pain-killing drugs… as well as illegal street drugs like
cocaine”.).
59
42 U.S.C. § 12114(a).
60
See 29 C.F.R. § 1630.3.
61
Equal Employment Opportunity Commission, Technical Assistance Manual on the Employment Provisions (Title
I) of the Americans with Disabilities Act, §8.2, https://askjan.org/publications/ada-specific/Technical-AssistanceManual-for-Title-I-of-the-ADA.cfm#spy-scroll-heading-74.
62
Id. (“An applicant or employee who tests positive for an illegal drug cannot immediately enter a drug
rehabilitation program and seek to avoid the possibility of discipline or termination by claiming that s/he now is in
55
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Although courts have not set a firm timeline in defining “current”, multiple courts have
discussed the meaning of a “current” use under the ADA.63 In Zenor v. El Paso Healthcare
Systems, Ltd.64, an employee was discharged five weeks after he had used cocaine.65 The court
determined that because he had used cocaine five weeks prior to his discharge, he was not
entitled to ADA protection.66
Employees who assert that they are in a drug rehabilitation treatment program can still be
considered “current” users.67 In Salley v. Circuit City Stores, Inc.68, the employee had a long
history of addiction to heroin, but was drug-free for 10 years.69 The employee suffered a relapse
and sought treatment.70 After the employer took action against the employee, the court analyzed
whether the employee was protected by the ADA.71 In holding that he was not, the court noted
that a three week period since last use was entirely too short to make the employees use not
“current”.72 In Shafer v. Preston Memorial Hospital Corp.73, the court assessed the meaning of
“current” under the ADA when an employee was addicted to prescription medication.74 The
employee then entered rehabilitation.75 After she completed rehabilitation, she was discharged.76

rehabilitation and is no longer using drugs illegally. A person who tests positive for illegal use of drugs is not
entitled to the protection that may be available to former users who have been or are in rehabilitation.”.)
63
See Zenor v. El Paso Healthcare Systems, Ltd., 176 F.3d 847 (5th Cir. 1999) (defining “current” illegal drug use
when an issue arose whether drug use five weeks prior was “current”); see, e.g., Salley v. Circuit City Stores, Inc.,
160 F.3d 977 (3d Cir. 1998); Shafer v. Preston Memorial Hospital Corp., 107 F.3d 274 (4th Cir. 1997).
64
Zenor, 176 F.3d 847 (5th Cir. 1999).
65
Id. at 852.
66
Id. at 867.
67
See Salley, 160 F.3d 977 (3d Cir. 1998); Shafer, 107 F.3d 274 (4th Cir. 1997); Collings v. Longview Fibre Co., 63
F.3d 828 (9th Cir. 1996).
68
Salley, 160 F.3d 977 (3d Cir. 1998).
69
Id. at 978.
70
Id. at 979.
71
Id.
72
Id. at 980 (“[there is] no case in which a three-week period of abstinence has been considered long enough to take
an employee out of the status of ‘current’ user.”).
73
Shafer., 107 F.3d 274.
74
Id. at 275.
75
Id.
76
Id.
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In finding that the employee was a “current” user, the court noted that someone is a “current”
user if drugs had been used “in a periodic fashion during the weeks and months prior to
discharge.”77 In Collings v. Longview Fibre Co.78, several employees were fired for illegal drug
use, although they had completed a rehabilitation program.79 These employees even took drug
tests to show that they were not using when they were fired.80 Despite this, in finding that the
employees were not protected by the ADA, the court held that “current” use did not mean “on
the day of, or within a matter of days or weeks before,” but meant the use of drugs “recently
enough to indicate the individual actively engaged in such conduct.”81 Although courts have not
consistently defined “current” under the ADA, it is clear that employees suffering from SUD
may be unprotected by the ADA, even when they have not used drugs for months or have
completed rehabilitation.
EMPLOYER’S DEFENSE OF A “DIRECT THREAT”
The ADA allows employers to require that employees do not “pose a direct threat to the
health or safety of other individuals in the workplace.”82 A “direct threat” is defined as “a
significant risk to the health or safety of others that cannot be eliminated by reasonable
accommodation.”83 This provision may be used by an employer to “deny a job or benefit to an
individual with a disability.”84 Generally, under the ADA, when determining if a disabled
employee poses a direct threat, the analysis focuses on whether the employee has the capacity to

Id. at 278 (““the ordinary or natural meaning of the phrase ‘currently using drugs’ does not require that a drug
user have a heroin syringe in his arm or a marijuana bong to his mouth at the exact moment contemplated… [rather
someone is “current” if drugs were used] in a periodic fashion during the weeks and months prior to discharge.”).
78
Collings, 63 F.3d 828 (9th Cir. 1998).
79
Id. at 830.
80
Id. at 833.
81
Id.
82
42 U.S.C. § 12113(b).
83
42 U.S.C. § 12111(3).
84
42 U.S.C. § 12113(a).
77
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safely perform their job.85 In making this determination the “factors to be considered include:
(1) [t]he duration of the risk; (2) [t]he nature and severity of the potential harm; (3) [t]he
likelihood that the potential harm will occur; and (4) [t]he imminence of the potential harm.”86
The EEOC has noted that an employer may not discriminate against an employee just because of
a slight increased risk, rather, the risk must be substantial.87
Although the EEOC has attempted to define a “direct threat”, courts have also been
forced to analyze its meaning under the ADA.88 In EEOC v. Exxon Corp.,89 the District Court
analyzed the “direct threat” and its effect on an ADA discrimination claim.90 In that case, the
EEOC attempted to enforce the remedies of the ADA on behalf of numerous employees.91 The
employees were Exxon employees who had been working as engineers and had subsequently
been demoted to mechanics when their history of drug and alcohol abuse were discovered.92
One employee had abused prescription medication when he was 19, subsequently entered
rehabilitation and joined Exxon when he was in his 40s.93 Another employee had entered
rehabilitation for alcoholism before joining Exxon and had never experienced a relapse while at
Exxon.94
In the suit, the EEOC alleged that Exxon’s policy, which prevented employees who had
undergone some sort of SUD treatment but were employed in “safety-sensitive designated

85

29 C.F.R. § 1630.2(r).
Id.
87
Supra note 56 at § 8.7 (“[an employer may not deny benefits or employment] merely because of a slightly
increased risk. The risk can only be considered when it poses a significant risk, i.e., high probability of substantial
harm; a speculative or remote risk is insufficient.”).
88
See EEOC v. Exxon Corp., 967 F.Supp. 208 (N.D. Tex. 1997); reversed 203 F.3d 871 (5th Cir. 2000).
89
Id.
90
Id.
91
Id. at 209.
92
Id. at 210-11.
93
Id.
94
Exxon, 967 F.Supp at 210-11.
86
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positions” was in violation of the ADA.95 The EEOC argued that the blanketed policy
discriminating against all individuals who had a history of SUD violated the ADA because it did
not utilize the ADA safety factors.96 Exxon argued that the ADA does not mandate such an
individualized assessment.97 Exxon further asserted that “that the risk of relapse of any
rehabilitated substance abuser is too great for certain types of jobs such that individual
assessment is futile.”98 The District Court, in rejecting the EEOC and employees’ claims held
that the ADA contains an exception to the individualized factors required.99 The District Court
emphasized the need for protecting employers from the risks created by patients who had
undergone SUD treatment.100 The District Court also pointed to other discrimination statues that
allow blanketed exclusions from certain positions when safety is at issue.101
On appeal, the EEOC argued that employers must meet the “direct threat” defense,
codified in 42 U.S.C. § 12113(b)102.103 The 5th Circuit held that although the ADA’s “direct
threat” defense is an individual analysis, the “business necessity”104 defense allows for an acrossthe-board blanketed policy.105 Using the analysis, the Court held that an employer may use the

95

Id.
Id.; supra note 81 (listing the factors an employer must consider).
97
Exxon, 867 F.Supp. at 211.
98
Id. at 210.
99
Id. at 213.
100
Id. at 212 (“[A]s courts define the scope of the ADA's coverage of employees who have illegally used drugs, they
underscore the need to protect employers from the risks posed by recently rehabilitated employees.”).
101
Id. (“The Rehabilitation Act, the Age Discrimination in Employment Act ("ADEA"), and Title VII also provide
guidance because these statutes are similar in purpose to the ADA and have often been relied upon in interpreting
the ADA.”).
102
42 U.S.C. § 12113(b).
103
EEOC v. Exxon Corp., 203 F.3d 871, 873 (5th Cir. 2000) (“With regard to safety sensitive requirements that
screen out or tend to screen out an individual with a disability or a class of individuals with disabilities, an employer
must demonstrate that the requirement, as applied to the individual, satisfies the “direct threat” standard . . . in order
to show that the requirement is job-related and consistent with a business necessity.”).
104
42 U.S.C. § 12113(a).
105
EEOC, 203 F.3d at 874 (“While no court has as yet addressed the question we answer today, several trends in
ADA case law indicate that the direct threat test is not deployed where an employer uses a general safety-based
qualification standard applicable across-the-board.”).
96
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“business necessity” defense, without conducting an individual analysis as to each employee, to
enact an across-the-board policy, effectively discriminating against SUD patients who had no
relapses during their employment.106
In sum, the ADA allows employers to require that an employee does not pose a “direct
threat” to the workplace. Normally, this analysis considers each individual employee. However,
when employers use the “business necessity” defense in conjunction with the “direct threat”
defense, courts have allowed employers to utilize blanketed catch-all guidelines without
considering the needs of individual employees. These company-wide sweeping guidelines have
resulted in policies personally effecting patients who had been treated for SUD and have not
relapsed.
PART V: LOBBYING EFFORTS TO AMMEND 42 C.F.R.§ 2
Recently, many groups, specifically health care providers have argued that Part 2 must be
amended.107 Proponents of amending Part 2 offer 3 arguments to support amending.108 These
arguments are: (i) Part 2 is outdated and not aligned with HIPAA109, preventing the efficient
sharing of medical records between providers110; (ii) Part 2 perpetuates stigma against SUD
patients by treating SUD records differently from other diseases111; and (iii) Part 2 increases
costs for healthcare providers112 This comment will dissect each argument in turn.

Id. at 875 (“We have found nothing in the statutory language, legislative history or case law that persuades that
the direct threat provision addresses safety-based qualification standards in cases where an employer has developed
a standard applicable to all employees of a given class.”).
107
See Sarah E. Wakeman, Peter Friedmann “Outdated Privacy Law Limits Effect Substance Use Disorder
Treatment: The Case Against 42 CFR Part 2” Health Affairs, March 1, 2017, available at
https://www.healthaffairs.org/do/10.1377/hblog20170301.058969/full/ (arguing for the amending of Part 2); supra
note 35 at 6057-6061 (summarizing public feedback to potential amendments of Part 2).
108
Wakeman, et. al supra note 102; supra note 35.
109
42 U.S.C. §1320d-6.
110
Wakeman, et. al supra note 102.
111
Id.
112
Supra note 35 at 6058.
106
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THE ARGUMENT THAT PART 2 IS OUTDATED
One argument posed by proponents of amending Part 2 is that the added layer of
protection provided by Part 2 hinders efficient medical care.113 These proponents also argue that,
because Part 2 was enacted before HIPAA, these regulations are no longer needed.114
Specifically, proponents argue that in the present age of patients being treated for SUD in a
primary care setting, Part 2 prevents providers from utilizing electronic health records, and
exchanging information.115 Other proponents, believing that SUD should be treated in the
broader general medical care setting, argue that Part 2 hinders the facilitation of electronic
exchange of SUD records which results in patients receiving sub-par care.116 Believing that
patients should be treated for SUD in a general healthcare setting, some argue that Part 2 should
be amended to allow all healthcare providers to see SUD treatment records.117 Apart from
arguing that SUD patients should be treated in the general healthcare setting, some argue that
Part 2 maintains barriers impeding the sharing of information needed for coordinated care, even
if SUD is not treated in a general healthcare setting.118 Supports of amending Part 2 argue that
these barriers may result in providers being unaware of a patient’s medical history.119 In terms of
HIPAA, supporters of amending Part 2 point to the fact that Part 2 was enacted before HIPAA,

Id. (“Designed to protect stigmatized patients, ironically this added layer of protection now creates virtual care
silos, hinders good medical care…in the contemporary era of electronic health records (EHRs), health information
exchanges, behavioral health integration, and HIPAA privacy protections.”).
114
Wakeman, et. al supra note 102 (“The intentions of 42 CFR part 2 were good and necessary in the era before the
Health Insurance Portability and Accountability Act of 1996 (HIPAA).”).
115
Supra note 35 at 6057.
116
Id. at 6058 (supporting the “facilitation of electronic exchange of [SUD] treatment” because separate restrictions
“ultimately negatively impacts patients and the care they receive[.]”.
117
Id. (arguing that “[SUD records] should be accessible to all healthcare facilities for the sole purpose of better
treating … patients.”).
118
Id. (Part 2 creates “barriers and create additional barriers that impede the sharing of information exchange and
care coordination[.]”).
119
Id. at 6057 (“the current practice of keeping [SUD records] separate from [other records] … could contribute to
providers missing critical information needed for treating patients.”).
113

15

and these protections are no longer needed.120 They assert that, because Part 2 is no longer
needed due to HIPAA, Part 2 should be aligned with HIPAA, maintaining privacy while
providing efficient care.121
THE ARGUMENT THAT PART 2 PERPETUATES STIGMA
Another argument made in support of amending Part 2 is that the added privacy
protections mandated by Part 2 perpetuate stigma.122 This argument assumes that, because
legislation treats certain records “differently”, the legislature is sending the message that these
records are secret and shameful.123 Separating SUD from other records is hypocritical, argue
supporters of amending Part 2.124 The reasoning is as follows: by safeguarding these records, we
are sending a message that SUD is not just like any other disease.125 Asserting that SUD records
should be treated like any other records, some argue that this added stigma ultimately impacts the
type of care SUD patients receive.126

Wakeman, et. al supra note 102 (“The intentions of 42 CFR part 2 were good and necessary in the era before the
Health Insurance Portability and Accountability Act of 1996 (HIPAA).”).
121
Supra note 35 at 6060 (“[A]ligning [Part 2} with HIPAA would help to strike an appropriate balance between
protecting sensitive health information while providing coordinated care.”); Id. (“[Aligning Part 2 with HIPAA
would] broaden the allowable sharing of data for purposes of .. patient safety.”). The arguments for the purpose of
patient safety assert that without integrated care, a doctor, unaware of a patient’s SUD may accidently prescribe an
opioid when doing so would not be appropriate. Wakeman, et. al supra note 102 (“ Imagine the harm that occurs
when a patient with opioid use disorder goes to see a physician who is not able to see that patient's diagnosis due to
42 CFR part 2, and unknowingly prescribes opioids.”).
122
Id. (“[Part 2’s] added layer of protection … perpetuates stigma[.]”); see also id at 6057 (“Some …asserted that
maintaining a separate set of confidentiality restrictions aimed solely at [SUD] providers and patients perpetuates the
discrimination associated with [SUD][.]”.
123
Wakerman, et. al supra note 102 (“Requiring additional releases perpetuates stigma by sending the message that
these are secret, shameful conditions that must be treated differently from any other disease.”).
124
Id. ("The message is also hypocritical: physicians and patients are told addiction is a disease like any other, but
also that this disease requires a level of secrecy higher than diabetes, cancer, or HIV.”).
125
Id.
126
Supra note 35 at 6058 (“maintaining a separate set of confidentiality restrictions aimed solely at substance use
disorder providers and patients perpetuates the stigma associated with substance use disorder and ultimately
negatively impacts patients and the care they receive, suggesting that issues of substance use disorder information
confidentiality should be part of the broader general medical care confidentiality regulations.”).
120
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THE ARGUMENT THAT PART 2 IMPOSES EXTRA COSTS ON HEALTHCARE
PROVIDERS
The last argument posed in support of amending Part 2 is that its added restrictions result
in added costs to healthcare providers.127 Because Part 2 mandates that SUD records are kept
separate from ordinary medical records, hospitals are required to maintain separate log-ins to
access both types of records.128 Essentially, some argue that the burden of added administrative
costs of separating SUD from other records outweighs any benefits created by Part 2.129
Proponents of amending Part 2 use the added costs that Part 2 imposes on providers to justify the
proposition that facilities are less likely to implement SUD programs.130 Finding that SUD
patients are “the highest cost utilizers in the health care system”, supporters of amending Part 2
also assert that the added protections created by Part 2 are particularly costly on the healthcare
system.131 In sum, advocates of amending Part 2 believe that because Part 2 adds costs on
healthcare providers, it should be amended to align with other privacy laws, allowing for easier
access and compliance for providers.
Multiple arguments are advanced by supporters of removing Part 2’s added privacy
protections.132 Among these arguments are: (i) Part 2 is outdated and SUD records should be

Id. (“[Part 2] maintain[s]… high compliance costs [on providers].”).
Wakerman, et. al supra note 102 (“At many hospitals, the EHR systems require a separate log-in to access
records sequestered under 42 CFR part 2. These additional administrative burdens are hardly a selling point to new
clinicians at a time when we need more physicians willing to care for patients with addiction.”).
129
Id.
130
Supra note 35 at 6058 (“[P]art 2 regulations keep the [SUD] treatment system isolated from general health care
providers and reduce access to [SUD] treatment being added by general health care organizations, which due to
administrative burden and liability fears, are less likely to add [SUD] treatment.”); see id. (“[P]art 2 regulations have
unintended consequences, including… the burdens associated with constantly updating expiring consents.”).
131
Id. (“[T]he burdens caused by [Part 2] are particularly costly because patients with [SUD] are among the highest
cost utilizers in the healthcare system.”).
132
See id. (arguing that Part is outdated); see also id. at 6060 (arguing that Part 2 perpetuates stigma); see also id. at
6058 (arguing that Part 2 imposes significant costs on the healthcare system).
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treated like any other treatment records133; (ii) by separating SUD records from others and
requiring consent for disclosure134, Part 2 perpetuates stigma; and (iii) Part 2 imposes significant
costs on the healthcare system which outweigh any benefits created.135

PART VI: MONITORING TECHNOLOGY: PRESCRIPTION DRUG MONITORING
PROGRAMS
PDMPs are state enacted monitoring systems aimed at preventing the illicit overuse of
prescription drugs.136 First, this comment will explain PDMPs generally, then it will explain
current access to PDMPs by providers, then it will analyze current use of PDMPs by SUD
treatment providers specifically.
PDMPS GENERALLY
PDMPs are tools employed by healthcare providers and law enforcement to reduce
prescription drug abuse, misuse, and diversion.137 PDMPs record a patient’s prescription record
by collecting and monitoring data electronically submitted by prescribers and dispensers of
prescription drugs.138 The data is managed by each state and used by a variety of entities to: (i)
educate about prescription drug abuse; (ii) research prescription drug abuse; (iii) enforce action
against abusers or diverters; and (iv) prevent abuse.139 PDMPs can only be accessed by entities
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Supra note 103.
Supra note 117.
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Supra note 122.
136
PDMP Frequently Asked Questions FAQs), Prescription Drug Monitoring Program Training and Technical
Assistance Center (PDMP TTAC); https://www.pdmpassist.org/pdf/PDMP_FAQs.pdf.
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Id.; see also Prescription Drug Monitoring Programs: A Guide For Healthcare Providers, Substance Abuse and
Mental Health Services Administration (SAMHSA), https://store.samhsa.gov/system/files/sma16-4997.pdf
(describing PDMPs, their background, and funding sources).
138
PDMP TTAC supra note 131.
139
Id. (“The data are used to support states’ efforts in education, research, enforcement, and abuse prevention.
PDMPs are managed under the auspices of a state, district, commonwealth, or territory of the United States.”).
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authorized by law.140 In recent years, however PDMPs have served another serious function –
they allow prescribers the ability to get a complete picture of their patients in order to make a
more informed healthcare decision.141
Presently, all states including Washington D.C., Guam, and Puerto Rico have functioning
PDMPs.142 These PDMPs are administered by a variety of agencies including: (i) consumer
protection agencies; (ii) substance abuse agencies; (iii) professional licensing boards; (iv) law
enforcement entities; (v) departments of health; and (vi) boards of pharmacy143 Of the various
agencies administering the programs, pharmacy boards administer the majority.144 Each state
monitors drugs according to applicable federal and state controlled substances laws.145 For
example, 11 states monitor drugs scheduled II-IV, while 40 states Guam and Puerto Rico
monitor drugs scheduled II-V.146 Generally, PDMPs are updated on a daily or weekly basis,
adding information about patients and prescribing.147 This, however, is changing. Recently
states have implemented real time (emphasis added) reporting, allowing prescriptions to appear
on the PDMP within 5 minutes of dispensing.148 Although the state requirements vary regarding

Id. (“PDMPs do not interfere with appropriate medical use. [] Prescription data is provided only to entities
authorized by state law.”); id. (“PDMPs do not infringe on the legitimate prescribing of a controlled substance by a
practitioner acting in good faith and in the course of a professional practice.”).
141
Opioid abuse in th U.S. and HHS actions to address opioid-drug related overdoses and death, U.S. Department
of Health and Human Services, https://aspe.hhs.gov/basic-report/opioid-abuse-us-and%20-hhs-actions-addressopioid-drug-related-overdoses-and-deaths (“Advances in technology have enabled PDMPs to take on another
important role— that of an adjunct source of information that prescribers and pharmacists can use to improve the
care and safety of individual patients. Helping healthcare providers make the most informed prescribing and
dispensing decisions, as part of an initiative to address opioid-related overdoses and deaths, is a federal government
priority.”).
142
Supra note 131 (“All states, the District of Columbia, Guam, and Puerto Rico have operational [PDMPs].”).
143
Id.
144
Id.
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Id.
146
Id. (containing a chart showing the breakdown of states monitoring various drugs).
147
SAMHSA supra note 132 (“Most PDMPs update their data on a daily or weekly basis, enabling prescribers and
dispensers to assess a patient’s recent patterns of use or misuse.”).
148
Id. (“Oklahoma became the first state to institute real-time reporting, with prescription data available within 5
minutes after medication is dispensed.”) (internal citations omitted).
140
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when a prescriber or dispenser must check the PDMP149, the CDC suggests that both prescribers
and dispensers check the PDMP at least once every three months and prior to every opioid
prescription150 in order to monitor prescribing habits and patient safety. Although PDMPs
throughout the nation are updated and checked in accordance with state laws and do not adhere
to a uniform federal policy, PDMPs can be utilized by both prescribers and dispensers to monitor
illicit drug use, sometimes within minutes. Thus, PDMPs play an important role in the detection
and monitoring of drugs being improperly used.
CURRENT REGULATIONS GOVERNING PRESCRIBERS’ USE OF PDMPS
As mentioned above, different state laws regulate who can access PDMPs and their
records.151 Certain states may allow professionals such as nurse practitioners and physician
assistants as well as doctors and pharmacists to access the PDMP.152 This broad access is meant
so that various professionals can review a patient’s record from a PDMP to confirm their
prescription history and ensure that drugs are being used properly.153
In terms of the type of reports available to prescribers, regulations vary by state.154 For
example, 30 states allow prescribing professionals to see their: (i) patient’s prescription history;
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PDMP Mandatory Query by Prescribers and Dispensers, Prescription Drug Monitoring Program Training and
Technical Assistance Center (PDMP TTAC), https://www.pdmpassist.org/pdf/Mandatory_Query_20190827.pdf
(presenting a map demonstrating the requirements of each state).
150
Checking the PDMP: An Important Step to Improving Opioid Prescribing Habits, Center for Disease Control;
https://www.cdc.gov/drugoverdose/pdf/pdmp_factsheet-a.pdf (“State requirements vary, but the CDC recommends
checking at least once every 3 months and consider checking prior to every opioid prescription.”).
151
SAMHSA supra note 132 (“Depending on the particular state law, the types of professionals who may register to
access PDMP records [varies].”).
152
Id.
153
Id. (“To ensure that the patient does not misuse prescribed medication, the practitioner can monitor PDMP
data[.]”).
154
See PDMP Reports Available to Prescribers, PDMP TTAC,
https://www.pdmpassist.org/pdf/Reports_to_Prescribers_20190816.pdf (showing different types of reports
dispensed by each state’s PDMP).
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(ii) their own prescribing history; and (iii) query audit trail155.156 20 states allow access to only
the patient’s prescription history and their own prescribing history.157 One state allows
prescribers to see patient history and a query audit trail only, while two states allow access to
only patient history reports.158 Although states vary in terms of access to content, all PDMPs
across the nation allow prescribers to view a patient’s history, ensuring that patient safety is
always maintained.
There are also differences in state laws regarding how frequently and by which method a
healthcare professional receives and is required to check PDMP reports.159 Presently, 19 states
require both prescribers and dispensers to check the PDMP when prescribing or dispensing a
covered drug.160 27 states only require prescribers to check the PDMP in these instances, not
dispensers.161 7 states, however, do not require any PDMP check for qualified drugs.162 In these
situations, the PDMP is simply a resource for the prescriber and dispenser, not a mandatory step
in the prescription process. In terms of how prescribers receive reports from the PDMP, there
are two distinct scenarios.163 16 states send PDMP reports to prescribers only when the
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A query audit trail is a system that allows a healthcare professional to see who accessed their records and for
what reason. PDMP Delegate Account Systems, PDMP Center of Excellence, Brandeis University,
https://www.pdmpassist.org/pdf/PDMP_admin/Briefing%20on%20Delegate%20Account%20Systems.pdf.
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PDMP TTAC supra note 148.
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Id.
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Id.
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See PDMP Mandatory Query by Prescribers and Dispenser, PDMP TTAC,
https://www.pdmpassist.org/pdf/Mandatory_Query_20190827.pdf (showing differences between states in requiring
mandatory PDMP checks); see also Engaged in Sending Solicited and Unsolicited Reports to Prescribers, TTAC,
https://www.pdmpassist.org/pdf/Prescribers_Sol_Unsol_Reports_20190816.pdf, (showing differences between
states sending reports to prescribers).
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PDMP TTAC supra note 144.
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Id.
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Id.
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PDMP TTAC supra note 154 (showing differences in receiving PDMP reports).
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prescriber requests such material, whereas 37 states send PDMP reports to prescribers both when
they request the reports and randomly when not requested.164
Differences exist among: (i) who can access PDMPs; (ii) the types of reports available to
those who have access to the PDMPs; and (iii) the frequency and method of receiving such
reports. Even though these differences exist, the goals of PDMPs remains the same: to allow
both prescribers and dispensers of covered drugs to confirm a patient’s prescription history and
to ensure that prescriptions are used properly165.
USE OF PDMP DATA BY SUD TREATERS
Patients being treated for SUD are often treated in one of two settings; opioid treatment
programs (“OTPs”) and office-based opioid treatment programs (OBOTs).166 Both programs
allow patients access to medication such as methadone and naloxone.167 Because only OTPs are
covered by Part 2, a provider in an OTP setting who prescribed methadone is prohibited from
reporting the prescription to the PDMP.168 On the other hand, OBOT’s must disclose medication
to the PDMP.169 Only OTPs are relevant to this comment. Because OTPs do not disclose
prescriptions to the PDMP, theses prescribers must monitor their patients to ensure safety.170
Presently, 14 states allow SUD treatment programs to access the PDMP.171 Some states
require that OTPs query the PDMP as soon as the patient arrives at the facility.172 It should be
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SAMSHA supra note 137.
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Use of PDMP Data by Opioid Addiction Treatment Programs, PDMP Center of Excellence, Brandeis University,
https://www.pdmpassist.org/pdf/Resources/Use%20of%20PDMP%20data%20by%20opioid%20treatment%20progr
ams.pdf.
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noted that PDMP queries by SUD providers do not reveal their status to outside
providers.173Although there are no set guidelines for PDMP use by providers, the American
Association for Treatment of Opioid Dependence ("AATOD") recommends that providers who
have access to PDMPs utilize them in treating patients.174 Individual providers have enacted
practices utilizing PDMPs to better protect their patients’ interests.175 In Washington, for
example, providers check the PDMP as soon as the patient arrives and at least once every six
months to detect improper drug use.176 Providers also query the PDMP whenever: (i) a patient is
considered for take-home medication; (ii) the patient exhibits signs of impairment; (iii) the
patient exhibits a change in behavior, or (iv) tests positive for a controlled substance.177 These
policies, although not mandated by law, have yielded substantial results. In Delaware, providers,
by querying the PDMP frequently, discovered that patients were selling prescribed medication or
using them recreationally.178
Although PDMPs may serve as important resources to SUD providers, some have
complained about their integration into practice. Some providers found that the PDMPs were
non-intuitive and lacked integration with other health records.179 Providers also suggested that
support-staff should be granted access to the PDMP and allow a provider the ability to look up
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Guidance to OTPs Concerning the Use of Prescription Monitoring Program (PMP) Databases, American
Association for the Treatment of Opioid Dependence, http://www.aatod.org/policies/policy-statements/guidance-tootps-concerning-the-use-of-prescription-monitoring-program-pmp-databases/.
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See generally PDMP Center of Excellence, Brandeis University supra note 160 (explaining the practices
employed in North Carolina, Washington, Delaware, Vermont, and Massachusetts).
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all patients at once.180 Folks engaging in PDMP checks also noted that some PDMPs did not
provide for real-time patient updates, sometimes lagging behind by days or weeks.181
Although PDMPs have certain restrictions, it is clear that increased usage of PDMPs by
SUD providers may reap a number of benefits including revealing improper drug use. Providers
who have access to PDMPs, involved in a close relationship with the patient, are in a position to
monitor, identify, and remedy any potential abuse of drugs monitored by the PDMP.
PART VII: ANALYSIS: UTILIZING PDMPS TO ENSURE SUD PATIENT SAFETY
AND CONFIDENTIALITY
State PDMP programs should consider expanding access to SUD providers and mandate
frequent and consistent checks by these providers. By checking the PDMP frequently, SUD
providers will ensure that patients are not prescribed dangerous substances when they should not
be, filling in any potential gaps created by Part 2.
As discussed above, there have been many arguments advanced in support of amending
Part 2. Among these are: (i) Part 2 is outdated and prevents providers from seeing a patient’s full
medical history and may lead to overprescribing; (ii) Part 2 perpetuates stigma by separating
SUD records from other records; and (iii) Part 2 imposes excessive costs on healthcare providers.
By incorporating the use of PDMPs by SUD providers, these issues can be remedied, creating a
solution that focuses on patient safety while still maintaining Part 2 privacy.
Expanding PDMP access to providers who are treating patients for SUD and mandating
their use will ensure that patients are not overprescribed medication and remain safe. SUD
providers are in a position of trust with SUD patients. By allowing these providers to access the
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PDMP, they will be able to check what their patients are being prescribed. Providers will be able
to detect indiscriminate providing in two ways. First, these providers will detect improper
prescribing by their mandatory query of PDMP. For example, imagine a patient who is being
treated for SUD. The patient is likely to go to a doctor, who, because of Part 2 is unaware of the
patient’s SUD history, and that doctor may prescribe opioids which could be detrimental to the
patient’s health. However, the SUD provider, by querying the PDMP will be able to detect the
opioid prescription, discuss it with the patient, and make a more informed decision. This will
ensure that patient is safe without having the non-SUD provider see any SUD record. Second,
SUD providers will be able to query the PDMP whenever they suspect suspicious behaviors or
activity from their patients, thus uncovering and preventing any potential misuse. When a SUD
provider has access to the PDMP, they will be able to ensure their patients are not being
described dangerous drugs when they detect something unusual. The proposed solution ensures
that no over-prescribing occurs and that the drugs used by patients are consistently monitored.
Part 2’s privacy protections are essential and should not be removed. The argument that
Part 2, by separating SUD records from others, perpetuates stigma is wholly incorrect. As
mentioned above, not only are there stigma issues surrounding SUD, but real-life implications.
Patients are discriminated against in terms of housing rights, parental rights, and denied any
protection from anti-discriminatory laws. Separating the documents, protects from stigma, not
perpetuates it. This comment is filled with examples of patients who have not used drugs in
months or even years, and are still discriminated against due to stigma. If these records were
accessible by any employer or doctor, the results would be devastating for patients.
Patient privacy should never be compromised in favor of administrative ease. People
who believe that Part 2 must be amended frequently cite the added costs it creates. By separating
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records, providers are forced to use separate channels to check a patient’s records. Although Part
2 does imposes costs on providers, the benefits it provides severely outweigh those costs. As
mentioned, Part 2 allows patients to control who sees their medical records, protecting their
privacy. This added benefit should never be compromised just because a provider will be
required to spend a few extra minutes with each patient.
CONCLUSION
It is clear that SUD is a medical condition effecting millions of Americans annually.
Although medical research has shown that SUD is a medical condition, there exists negative
stigma surrounding SUD. People may view it as a moral failing or choice and reserve opinions
about patients who suffer from it. The results from this negative stigma can be harmful. Patients
suffering from SUD face consequences such as loss of housing and loss of parental rights, even
when they had not actively used any illegal drugs. Not only are SUD patients impacted legally
and logistically, but they are judged by healthcare providers who treat for reasons other than
SUD.
In order to confront and reduce some of the negative impacts of SUD stigma, Congress
enacted 42 C.F.R. Part 2. Part 2 provides essential protection to SUD patients, allowing them the
ability to decide who sees their medical records. Part 2 is also important because it is the only
federal legislation which protects SUD patients from the stigma surrounding their disease. As
mentioned above, the ADA, a major anti-discriminatory law, fails to protect patients with SUD
and would allow employers and landlords to treat individuals differently because they suffer
from SUD, even when they are not using any drugs.
Part 2 is not all positive, however. It comes with some serious flaws. Part 2, keeping
SUD documents separate from ordinary documents, may reduce the ability for non-SUD
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providers to see what a patient is prescribed and lead to improper prescribing. It is also argued
that by separating documents, Part 2 perpetuates stigma and increases costs on providers.
A solution, which allows providers to monitor their patients, however, exists. By
expanding PDMP access to SUD providers and mandating their use, states can find a solution
that would ensure providers monitor the PDMP frequently enough to detect indiscriminate
prescribing, while still keeping SUD records out of hands of those who do not need to see them,
preventing negative impacts of stigma. This solution will serve to both protect patient’s health
and privacy. Patient privacy, however, must never been compromised for the sake easing the
administrative tasks of providers. The stakes are entirely too high.
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